Company: BLLN
Filing Date: 2025-09-17
Form Type: DRS/A
Source: 0001193125-25-206347
Chunk: 4

Company: BillionToOne, Inc.
Filing Date: 2025-09-17
Form: DRS/A
Chunk 4
---
 3. Based on $0.1M EBITDA in Q2 2025 and ($0.2M) net loss in Q2 2025. 4. Our estimated US annual market opportunity includes important assumptions, including regarding the number of eligible patients, frequency of testing and ASPs. See Management's discussion and analysis of financial condition and results of operations > Key factors affecting our results of operations and performance for more information regarding our total addressable market calculations and assumptions. Half of this addressable market includes early detection, an area in which we have not yet begun specific product development or commercial sales, but we believe will be strongly enabled by our existing research platform. 5. Last twelve months (LTM) revenue. Equal to sum of each month's revenue over the prior 12 months ended Jun 30, 2025. 6. Number of billable tests received for processing. 7. Number of individuals covered under contracts with payors in the US as of Jun 30, 2025.

Our Impact Marina* was excited about her pregnancy at 9 weeks. That was when she took the Billion ToOne's UNITY Fetal RiskTM Screen test, which revealed she was a carrier for cystic fibrosis. However, the same report also showed her baby had an extremely low risk of having the disease (1 in 5000). While initially surprised, Marina felt much less anxious and more at ease with her pregnancy than she would have with traditional carrier screening. Traditional methods would have only identified her carrier status and required her partner to undergo further testing to assess the baby's risk. Juan* was unfortunately diagnosed with stage IV lung cancer.After his initial biopsy, Juan's doctor requested BilliontoOne's Northstar Select® blood test to help him determine which treatment would work best. Northstar Select uncovered EGFR mutation at 0.05% variant allele fraction (VAF), a highly actionable cancer variant that has a known targeted therapy. Cancers at this low level of VAF are often missed by other cancer tests**. Thanks to Northstar Select, Juan was able to start on the best therapy for his cancer and his doctor can easily monitor his progress using Northstar ResponseR. * Actual customer stories. Names have been changed to preserve patients' privacy and the photos are actor portrayals. ** Other liquid biopsy tests have an LOD that ranges between 0.25% - 0.50% (e.g. TSO500 at 0.5% VAF for SNVs)